Rathbones Group PLC Has $6.84 Million Position in Edwards Lifesciences Corporation $EW

Rathbones Group PLC decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 31.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 87,971 shares of the medical research company’s stock after selling 40,645 shares during the period. Rathbones Group PLC’s holdings in Edwards Lifesciences were worth $6,842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in shares of Edwards Lifesciences by 7.0% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after purchasing an additional 9,069 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Edwards Lifesciences by 13.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after buying an additional 10,078 shares during the period. Atlantic Union Bankshares Corp boosted its holdings in shares of Edwards Lifesciences by 2,240.9% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after buying an additional 11,384 shares during the period. OMERS ADMINISTRATION Corp grew its stake in Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after buying an additional 21,950 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after acquiring an additional 1,423,365 shares during the period. 79.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Barclays restated an “overweight” rating and set a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Truist Financial set a $89.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Stifel Nicolaus set a $110.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Canaccord Genuity Group set a $87.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, December 17th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $103.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $81.71 on Monday. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The company’s 50 day moving average price is $82.56 and its two-hundred day moving average price is $81.47. The firm has a market cap of $47.46 billion, a PE ratio of 44.65, a PEG ratio of 2.13 and a beta of 0.93. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 79,144 shares of company stock valued at $6,685,688 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.